ASLAN PHARMACEU/ADR (NASDAQ:ASLN) had its Buy ➝ Buy rating reiterated by HC Wainwright with a $8.50 price target

ASLAN PHARMACEU/ADR (NASDAQ:ASLN) had its Buy ➝ Buy rating reiterated by HC Wainwright with a $8.50 price target

Jan 14, 2019 (Market Exclusive via COMTEX) —

Analyst Ratings For ASLAN PHARMACEU/ADR (NASDAQ:ASLN)

Today, HC Wainwright reiterated its Buy rating on ASLAN PHARMACEU/ADR (NASDAQ:ASLN) with a price target of $8.50.

There are 3 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on ASLAN PHARMACEU/ADR (NASDAQ:ASLN) is Buy with a consensus target price of $10.50 per share, a potential 267.13% upside.

Some recent analyst ratings include

1/14/2019-ASLAN PHARMACEU/ADR (NASDAQ:ASLN) had its Buy ➝ Buy rating reiterated by HC Wainwright with a $8.50 price target 5/30/2018-ASLAN PHARMACEU/ADR (NASDAQ:ASLN) has coverage initiated with a Market Perform rating and $7.00 price target 5/30/2018-ASLAN PHARMACEU/ADR (NASDAQ:ASLN) has coverage initiated with a Buy rating and $16.00 price target 5/30/2018-ASLAN PHARMACEU/ADR (NASDAQ:ASLN) has coverage initiated with a Overweight rating

About ASLAN PHARMACEU/ADR (NASDAQ:ASLN)
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in developing therapeutics for global markets. It targets diseases that are highly prevalent in Asia, and orphan indications in the United States and Europe. The company’s product pipeline includes Varlitinib, a reversible small molecule pan-human epidermal growth factor receptor inhibitor that is being studied in global pivotal trials (TreeTopp) for biliary tract cancer, and conducting Phase 2/3 clinical trials for gastric cancer, as well as testing in a single-arm pivotal clinical trial in biliary tract cancer in China. It has exclusive global rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses. It is also developing ASLAN003, an orally active potent inhibitor of human dihydroorotate dehydrogenase that is in Phase 2 clinical trails to treat acute myeloid leukemia; and ASLAN004, an interleukin 4/interleukin 13 receptor antibody for

Read More Here...

Bookmark the permalink.